Rapid molecular test (SeptiFast®) reduced time for adjustment of antibiotic treatment in comparison with conventional blood cultures in critically ill sepsis patients: a randomized controlled clinical trial (preliminary results)
© Rodrigues et al.; licensee BioMed Central Ltd. 2013
Published: 5 November 2013
Sepsis is the main cause of death in ICUs all over the world. Early detection of the pathogen is essential for appropriate antimicrobial treatment.
Materials and methods
To evaluate the reduction in time of antimicrobial adjustment therapy in patients with sepsis comparing a rapid molecular test (SeptiFast®) with conventional blood cultures, a randomized controlled clinical trial was conducted between October 2012 and May 2013 in a cardiology hospital. Adult patients staying more than 48 hours in hospital with clinical suspicion of sepsis were included in the study. Blood samples were collected for cultures (BacT/ALERT®) and Septifast® test immediately prior to initiation of antibiotic therapy. Patients were allocated into two groups. In the Intervention Group (GI), Septifast® results were communicated to the medical researcher and antimicrobials were adjusted. In the Control Group (GII), Septifast® results were not informed and therapy adjustment was based on the blood culture. Registered in Clinical trials.gov (NCT 01450358).
Distribution of characteristics in the two groups
Intervention group (n= 17)
Control group (n= 29)
63 (46 to 75)
66 (39 to 85)
Hospital stay (mean, days)
32 (9 to 118)
31 (3 to 112)
APACHE II (mean)
17 (8 to 29)
17 (8 to 29)
Ejection fraction <40%
Receiving antibiotics prior to study
Patients with adjustment therapy based on SeptiFast®
Patients with adjustment therapy based on blood culture
Mean time (minutes) of adjustment therapy
Pathogens detected in SeptiFast®
P. aeruginosa (2), K. pneumonia/oxytoca (1), E. aerogenes/cloacae (1), S. marcescens (1), A. baumanii (1)
Pathogens detected in blood culture
S. aureus (4), K. pneumonia (2), M. morganii (1)
The rapid molecular test (SeptiFast®) reduced the time for adjustment of antibiotic treatment in comparison with conventional blood cultures in critically ill sepsis patients.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.